Chlorpheniramine for allergic symptoms, rhinitis, & urticaria

Chlorpheniramine is a first-generation anti-histamine that is used in the treatment of the following conditions:

  • Perennial and seasonal Allergic rhinitis, urticaria, and pruritus
  • Motion sickness

Chlorpheniramine Dose in Adults

 Oral use in patients with Allergic symptoms, rhinitis, urticaria, and pruritus:

  • Immediate-release formulations:
    • 4 mg 4 - 6 hourly (Maximum dose should not exceed 24 mg/day)
  • Extended-release tablets:
    • 12 mg twice daily (The maximum dose should not exceed 24 mg/day)

Off-label use in Motion sickness:

  • Immediate-release tablets:
    • 4 - 12 mg administered 3 hours prior to the inciting stimulus for motion sickness

Chlorpheniramine Dose in Childrens

Oral use for allergic symptoms and rhinitis

  • Immediate-release tablets and oral solutions:
    • Children 2-6 years of age:
      • 1 mg 4 - 6 hourly to a maximum daily dose of 6 mg/day
    • Children 6 - 11 years of age:
      • 2 mg 4-6 hourly to a maximum daily dose of 12 mg/day
    • Children older than 12 years and Adolescents:
      • 4 mg 4 - 6 hourly to a maximum daily dose of 24 mg/day
  • Extended-Release tablets
    • Children older than 12 years and Adolescents:
      • 12 mg twice daily to a maximum daily dose of 24 mg per day.

Pregnancy Risk Factor B

  • Its use in pregnancy has not been associated with birth defects and may be used in patients with rhinitis, urticaria, pruritis, and rash in pregnant women (Preferably use second-generation antihistamines)
  • To treat intrahepatic cholesterolemia of pregnancy, antihistamines should be avoided.

Use during breastfeeding:

  • It can be excreted in breastmilk, and can cause drowsiness or irritability in infants breastfed.
  • Breastfed infants need to be watched for irritability or drowsiness. 
  • Furthermore, the newer generation antihistamines should be preferred over the first generation antihistamines.
  • Antihistamines can also reduce serum prolactin levels and milk production.

Chlorpheniramine Dose in Kidney Disease:

The manufacturer has not recommended any dose adjustment in patients with renal disease.

Chlorpheniramine Dose in Liver Disease:

  • The manufacturer has not recommended any dose adjustment in patients with liver disease.
  • However, since, it is metabolized by the liver, it should be used with caution.

Common Side Effects of Chlorpheniramine:

  • Central nervous system:
    • Drowsiness (slight to moderate)
  • Respiratory:
    • Thickening of bronchial secretions

Less Common Side Effects of Chlorpheniramine:

  • Central nervous system:
    • Dizziness
    • Excitability
    • Fatigue
    • Headache
    • Nervousness
  • Endocrine & metabolic:
    • Weight gain
  • Gastrointestinal:
    • Abdominal pain
    • Diarrhea
    • Increased appetite
    • Nausea
    • Xerostomia
  • Genitourinary:
    • Urinary retention
  • Neuromuscular & skeletal:
    • Arthralgia
    • Weakness
  • Ophthalmic:
    • Diplopia
  • Renal:
    • Polyuria
  • Respiratory:
    • Pharyngitis

Contraindication to Chlorpheniramine:

  • Allergy to chlorpheniramine-maleate or any component of the formulation
  • Narrow-angle glaucoma
  • Bloat at the Bladder Outlet
  • Prostate hypertrophy symptoms
  • Acute asthmatic attacks
  • Peptic ulcer surgery
  • Pyloroduodenal obstruction
  • Due to the possibility of sudden infant death syndrome, avoid premature or term newborns.
  • Avoid using children's sleeping pills.

Warnings and Precautions

  • CNS depression:
    • It can cause CNS depression and sedation that could lead to mental or physical impairments. It should be used with caution by patients who are required to maintain mental alertness for tasks.
  • Cardiovascular disease
    • Patients suffering from cardiovascular disease such as hypertension or ischemic heart disease, should not take the drug.
  • Increased intraocular pressure
    • May precipitate glaucoma. Patients with elevated intraocular pressure should not use it.
  • Prostatic hyperplasia and urinary obstruction:
    • It can cause urinary retention in the elderly.​​​​​​​
  • Respiratory disease
    • When using the medication, those with asthma or chronic obstructive pulmonary disorders (COPD) should exercise caution. 
  • Thyroid dysfunction:
    • Patients with thyroid dysfunction should use it with caution.

Chlorpheniramine: Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy).

Acetylcholinesterase inhibitors Anticholinergic Agents may have a decreased therapeutic effect. Anticholinergic Agents can decrease the therapeutic effects of Acetylcholinesterase inhibitors.
Ajmaline High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Alcohol (Ethyl) CNS Depressants can increase the CNS depressant effects of Alcohol (Ethyl).
Alizapride CNS Depressants may increase the CNS depressant effects.
Amantadine Anticholinergic Agents may have an enhanced anticholinergic effect.
Amezinium Amezinium may have a stronger stimulatory effect if it is combined with antihistamines.
Amphetamines May lessen antihistamines' sedative effects.
Anticholinergic Agents Other Anticholinergic Agents may have an adverse/toxic effect.
Betahistine Betahistine's therapeutic effects may be diminished by antihistamines.
Botulinum Toxin-Containing Products Anticholinergic Agents may have an enhanced anticholinergic effect.
Brexanolone CNS Depressants can increase the CNS depressant effects of Brexanolone.
Brimonidine (Topical) CNS Depressants may increase the CNS depressant effects.
Bromopride CNS Depressants may increase the CNS depressant effects.
Cannabidiol CNS Depressants may increase the CNS depressant effects.
Cannabis CNS Depressants may increase the CNS depressant effects.
Chloral Betaine Anticholinergic drugs could be harmful or poisonous.
Chlorphenesin Carbamate CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
CloBAZam High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
CNS Depressants Can increase the toxic/adverse effects of CNS Depressants.
Cobicistat High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Moderate CYP2D6 inhibitors Might decrease metabolism of CYP2D6 substrates (High Risk with Inhibitors).
Darunavir High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Dimethindene (Topical). CNS Depressants may increase the CNS depressant effects.
Doxylamine If taken alongside other CNS Depressants, CNS Depressants may have a stronger CNS depressing impact. Management: The producer of the pregnancy-safe drug Diclegis (doxylamine/pyridoxine) particularly advises against combining it with other CNS depressants.
Dronabinol CNS Depressants may intensify the effects of CNS Depressants.
Esketamine CNS Depressants may intensify the effects of CNS Depressants.
Fosphenytoin-Phenytoin Chlorpheniramine may increase the serum concentration of Fosphenytoin-Phenytoin.
Gastrointestinal Agents (Prokinetic) Anticholinergic Agents can reduce the therapeutic effects of Gastrointestinal Agents (Prokinetic).
Glucagon Anticholinergic agents may increase the toxic/adverse effects of Glucagon. Particularly, there may be an increase in the likelihood of gastrointestinal adverse reactions.
HydrOXYzine CNS Depressants may increase the CNS depressant effects.
Imatinib High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Itopride Itopride's therapeutic effects may be diminished by anticholinergic agents.
Kava Kava CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
Lofexidine CNS Depressants may have a greater depressant effect on the brain. Management: Separate drug interaction monographs are available for drugs listed as an exception to this monograph.
Lumefantrine High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Magnesium Sulfate CNS Depressants may increase the CNS depressant effects.
MetyroSINE MetyroSINE may have a sedative effect that can be enhanced by CNS depressants.
Mianserin Anticholinergic Agents may have an enhanced anticholinergic effect.
Minocycline CNS Depressants may increase the CNS depressant effects.
Mirabegron Anticholinergic agents may increase the toxic/adverse effects of Mirabegron.
Mirtazapine CNS Depressants can increase the CNS depressant effects of Mirtazapine.
Nabilone CNS Depressants may increase the CNS depressant effects.
Nitroglycerin Anticholinergic medications may reduce Nitroglycerin's absorption. Anticholinergic drugs may slow down the sublingual nitroglycerin tablet's ability to dissolve, which could hinder or delay nitroglycerin absorption.
Panobinostat High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Peginterferon Alfa-2b Inhibitors carry a high danger. may reduce the levels of CYP2D6 substrates in serum. Serum levels of CYP2D6 Substrates may rise after administration of peginterferon Alf-2b.
Perhexiline Perhexiline may be increased by CYP2D6 Substrates. Perhexiline can increase serum concentrations of CYP2D6 substrates (High Risk with Inhibitors).
Piribedil CNS Depressants could increase the CNS depressant effects of Piribedil.
Pitolisant Antihistamines can reduce the therapeutic effects of Pitolisant.
Pramipexole Pramipexole may have a greater sedative effect if it is combined with CNS depressants.
QuiNINE High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
Ramosetron Ramosetron's constipating effects may be enhanced by anticholinergic agents.
ROPINIRole CNS Depressants can increase the sedative effects of ROPINIRole.
Rotigotine CNS Depressants can increase the sedative effects of Rotigotine.
Rufinamide CNS Depressants may have an adverse/toxic effect that can be exacerbated by this. Particularly, dizziness and sleepiness may be increased.
Selective Serotonin Reuptake inhibitors CNS Depressants can increase the toxic/adverse effects of Selective Serotonin Resuptake Inhibitors. Particularly, psychomotor impairment could be increased.
Tetrahydrocannabinol CNS Depressants may increase the CNS depressant effects.
Tetrahydrocannabinol, and Cannabidiol CNS Depressants may increase the CNS depressant effects.
Thiazide and Thiazide - Like Diuretics Anticholinergic Agents can increase serum Thiazide or Thiazide-Like Diuretics.
Topiramate Topiramate's toxic/adverse effects may be exacerbated by anticholinergic agents.
Trimeprazine CNS Depressants may intensify the effects of CNS Depressants.

Risk Factor D (Consider therapy modifications)

 
Abiraterone Acetate High risk of Inhibitors causing an increase in serum concentrations of CYP2D6 substrates. When possible, avoid concurrent use of abiraterone and CYP2D6 Substrates with a narrow therapeutic index. If concurrent use cannot be avoided, closely monitor patients for signs and symptoms of toxic effects.
Asunaprevir High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates
BenzylpenicilloylPolylysine Antihistamines may reduce BenzylpenicilloylPolylysine's ability to diagnose. Management: Delay testing until systemic antihistaminic effects have subsided and discontinue systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing. A histamine skin test can be used to check for lingering antihistaminic effects.
Blonanserin CNS Depressants can increase the CNS depressant effects of Blonanserin.
Buprenorphine CNS Depressants can increase the CNS depressant effects of buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Buprenorphine patches (Butrans) should be initiated at 5 mg/hr for adults when taken with other CNS depression drugs.
Chlormethiazole CNS Depressants may increase the CNS depressant effects. Monitoring: Look out for signs of CNS depression. If a combination of chlormethiazole and other drugs is required, a reduced dose should be used.
Strong CYP2D6 inhibitors Might decrease metabolism of CYP2D6 substrates (High Risk with Inhibitors).
Dacomitinib High risk of Inhibitors causing an increase in serum concentrations of CYP2D6 substrates. Management: Do not use dacomitinib concurrently with CYP2D6 Substrates that have a narrow therapeutic Index.
Droperidol CNS Depressants may increase the CNS depressant effects. Management: Droperidol and other CNS agents, such as opioids, may be reduced or used in combination with droperidol. Separate drug interaction monographs provide more detail on exceptions to this monograph.
Flunitrazepam CNS Depressants can increase the CNS depressant effects of Flunitrazepam.
Hyaluronidase Antihistamines may lessen the therapeutic effects of hyaluronidase. Treatment: Patients taking antihistamines, especially at larger doses, may not respond clinically to hyaluronidase at conventional doses. Hyaluronidase dosages may need to be increased.
HYDROcodone CNS Depressants can increase the CNS depressant effects of HYDROcodone. When possible, avoid concomitant use with hydrocodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Methotrimeprazine Methotrimeprazine may have a higher CNS depressant activity than CNS Depressants. Methotrimeprazine can increase the CNS depressant effects of CNS Depressants. Management: Lower the adult dose of CNS Depressants by 50% and start concomitant methotrimeprazine treatment. After clinically proven efficacy of methotrimeprazine, further CNS depressant dose adjustments should only be made.
Opioid Agonists CNS Depressants can increase the CNS depressant effects of Opioid Aggonists. Management: When possible, avoid concomitant use opioid agonists and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
OxyCODONE CNS Depressants can increase OxyCODONE's CNS depressant effects. When possible, avoid the simultaneous use of oxycodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Perampanel CNS Depressants may have a greater CNS depressant effect. Perampanel and any other CNS depressant drug should be used in combination. Patients who take perampanel together with any other drug should not engage in complex or high-risk activities until they have had experience with the combination.
Pramlintide Anticholinergic Agents may have an enhanced anticholinergic effect. These effects are only for the GI tract.
Secretin Secretin's therapeutic effects may be diminished by anticholinergic agents. Concomitant use: Secretin and anticholinergic agents should be avoided. Stop using anticholinergic drugs for at least five half-lives before administering secretin.
Sodium Oxybate CNS Depressants may have a greater depressant effect if taken in combination. Management: Look for alternatives to the combination use. If you must combine use, reduce the doses of any one or more drugs. It is not recommended to combine sodium oxybate and alcohol, or any sedative hypnotics.
Suvorexant CNS Depressants can increase the CNS depressant effects of Suvorexant. Management: Suvorexant or any other CNS depressionant can be reduced in doses. Suvorexant should not be taken with alcohol. It is also not recommended to take suvorexant along with any other drugs for insomnia.
Tapentadol CNS Depressants may increase the CNS depressant effects. Tapentadol, benzodiazepines and other CNS depressants should be avoided when possible. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Thioridazine Thioridazine may have an arrhythmogenic effect that is enhanced by Chlorpheniramine. The serum concentration of Chlorpheniramine may be increased by Thioridazine. Management: If possible, avoid this combination. Monitor closely for arrhythmia and general toxicity of chlorpheniramine if you use it.
Zolpidem CNS Depressants can increase the CNS depressant effects of Zolpidem. Management: For men who also take CNS depressants, reduce the adult Intermezzo brand sublingual Zolpidem dose to 1.75mg. For women, no dose adjustment is advised. Avoid using CNS depressants at night; do not use alcohol.

Risk Factor X (Avoid Combination)

 
Aclidinium Anticholinergic Agents may have an enhanced anticholinergic effect.
Azelastine (Nasal CNS Depressants could increase the CNS depressant effects of Azelastine.
Bromperidol CNS Depressants may increase the CNS depressant effects.
Cimetropium Cimetropium may have an anticholinergic effect that can be enhanced by the use of anticholinergic agents.
Eluxadoline Eluxadoline may cause constipation by using anticholinergic agents.
Glycopyrrolate (Oral Inhalation) Anticholinergic agents may increase the anticholinergic effects of Glycopyrrolate (Oral inhalation).
Glycopyrronium (Topical) Anticholinergic Agents may have an enhanced anticholinergic effect.
Oral Inhalation with Ipratropium Anticholinergic Agents may have an enhanced anticholinergic effect.
Levosulpiride Anticholinergic Agents can reduce the therapeutic effects of Levosulpiride.
Orphenadrine Orphenadrine may be more effective against CNS depression than other drugs.
Oxatomide Anticholinergic Agents may have an enhanced anticholinergic effect.
Oxomemazine CNS Depressants may increase the CNS depressant effects.
Paraldehyde Paraldehyde may be enhanced by CNS depressants.
Potassium Chloride Potassium Chloride may have an ulcerogenic effect that can be exacerbated by anticholinergic agents. Treatment: Patients taking drugs that have significant anticholinergic effects should not consume any oral dose form of potassium chloride.
Potassium Citrate If potassium citrate is administered with anticholinergic drugs, it can increase the risk of ulcers.
Revefenacin Revefenacin may be enhanced by anticholinergic agents.
Thalidomide CNS Depressants can increase Thalidomide's CNS depressant effects.
Tiotropium Anticholinergic agents may increase the anticholinergic effects of Tiotropium.
Umeclidinium Anticholinergic Agents may have an enhanced anticholinergic effect.

Monitoring Parameters:

None required. Monitor symptoms control.

How to Administer Chlorpheniramine?

  • It may be administered with food or water.
  • When used for motion sickness, it should be administered 3 hours before the stimulus.
  • It should not be crushed or chewed and swallowed as a whole. 

Mechanism of action of Chlorpheniramine:

It is an anti-allergic medication that works by competing with histamine receptors located in the gastrointestinal tract, blood vessels and respiratory tract.

It is 33%Protein-boundAndMetabolizedby the liver via CYP450 enzymes. It is aHalf-lifeThe time taken to reach the destination can vary from 6 to 24 hours.peak plasma concentrationIt takes between 1 and 6 hours. 

It isexcretedPrimarily via urine

International Brands of Chlorpheniramine:

  • Aller-Chlor
  • Allergy Relief
  • Allergy
  • Allergy-Time
  • Chlor-Trimeton Allergy
  • Chlor-Trimeton
  • Ed Chlorped Jr
  • Ed ChlorPed
  • Ed-Chlortan
  • Pharbechlor
  • Acira
  • Ahiston
  • Alergidryl
  • Alergitrat
  • Aller
  • Allerfin
  • Allergex
  • Allermin
  • Allermine
  • Alleryl
  • Analer
  • Analerg
  • Anallerge
  • Antamin
  • Bregamin
  • Cadistin
  • Chlofen
  • Chloramine
  • Chlorohistal
  • Chlorohistan
  • Chlorohistol
  • Chlorpheniramine DHA
  • Chlorpheno
  • Chlorphenon
  • Chlorpyrimine
  • Chlortrimeton
  • Cipium
  • Clorfam
  • Cloro Trimeton
  • Cloro-Trimeton
  • Cloroalergan
  • Cohistan
  • Com-Trimeton
  • Derimeton
  • Histafen
  • Histal
  • Histalex
  • Histan
  • Histant
  • Histat
  • Histatapp
  • Histavil
  • Histon
  • Histop
  • Horamine
  • Isticol Jarabe
  • Lergisina
  • Lorecare
  • Nipolen
  • Niramine
  • Orphen
  • Peniramin
  • Pheneton 4
  • Pheniram
  • Piriton
  • Prodel
  • Sensitamine
  • Sprinsol
  • Trimeton
  • Valemine

Chlorpheniramine Brands in Pakistan:

Chlorpheniramine (Maleate) [Inj 10 mg/ml]

CHLOR FRIENDS PHARMA (PVT) LTD
CHLORPHENIRAMINE ORIENT LABORATORIES
CHLORPHENIRAMINE GEOFMAN PHARMACEUTICALS
CHLORPHENIRAMINE PLIVA PAKISTAN (PVT) LIMITED
HAMZIVIL ELITE PHARMA

Chlorpheniramine(Maleate) [Syrup 2 mg/5ml]

ALLERGEX NABIQASIM INDUSTRIES (PVT) LTD.
ALLERGON MEDICRAFT PHARMACEUTICALS (PVT) LTD.
ALLERMINE KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
ALLERMINE KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
ALLERPHENE P.D.H. PHARMACEUTICALS (PVT) LTD.
CEPIAM ARDIN PHARMACEUTICALS
CHLORPHENIRAMINE LISKO PAKISTAN (PVT) LTD
CHLORPHENIRAMINE ORTA LABS. (PVT) LTD.
CHLORPHENIRAMINE MIAN BROTHERS LABORATORIES (PVT) LTD.
CHLORPHENIRAMINE KARACHI PHARMACEUTICAL LABORATORY
CHLORPHENIRAMINE EROS PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE JAWA PHARMACEUTICALS(PVT) LTD.
COLEN ALLIANCE PHARMACEUTICALS (PVT) LTD.
FENRAM ALBRO PHARMA
HISTAGIC LISKO PAKISTAN (PVT) LTD
HISTALON POLYFINE CHEMPHARMA (PVT) LTD.
LOLRPHINE NEUTRO PHARMA (PVT) LTD.
NIRMINE DAVIS PHARMACEUTICAL LABORATORIES
PHEMIN MARVI LABORATORIES
PHENAMINE MUNAWAR PHARMA (PVT) LTD.
PHENERMIN SEMOS PHARMACEUTICALS (PVT) LTD.
REPHENIRAMINE SYNTEX PHARMACEUTICALS
RESMIN RASCO PHARMA
RHINOL IRZA PHARMA (PVT) LTD.
STAITON STANDARD DRUG CO.
UNIHIST UNISON CHEMICAL WORKS

Chlorpheniramin (Maleate) [Syrup 2.5 mg/5ml]

SYPRITON SAYYED PHARMACEUTICALS

Chlorpheniramine (Maleate) [Tabs 4 mg]

ALLERMINE KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
ALLERPHENE P.D.H. PHARMACEUTICALS (PVT) LTD.
ALLERVIL INDUS PHARMA (PVT) LTD.
ALPHEM ALSON PHARMACEUTICALS
APITON EURO PHARMA INTERNATIONAL
BARITON BATALA PHARMACEUTICALS.
CHLOFAMIN ALFALAH PHARMA (PVT) LTD.
CHLOROPHENIRAMINE MALEATE IRZA PHARMA (PVT) LTD.
CHLORPHENIRAMINE KARACHI PHARMACEUTICAL LABORATORY
CHLORPHENIRAMINE PHARMACARE LABORATORIES (PVT) LTD.
CHLORPHENIRAMINE IDEAL PHARMACEUTICAL INDUSTRIES
CHLORPHENIRAMINE MIAN BROTHERS LABORATORIES (PVT) LTD.
CHLORPHENIRAMINE MUNAWAR PHARMA (PVT) LTD.
CHLORPHENIRAMINE SEMOS PHARMACEUTICALS (PVT) LTD.
CHLORPHENIRAMINE UNEXO LABS (PVT) LTD.
CHLORPHENIRAMINE XENON PHARMACEUTICALS (PVT) LTD.
CHLORPHENIRAMINE LISKO PAKISTAN (PVT) LTD
CHLORPHENIRAMINE EROS PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE ARDIN PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE JAWA PHARMACEUTICALS(PVT) LTD.
CHLORPHENIRAMINE MALEATE ETHICAL LABORATORIES (PVT) LTD.
DEEMINE DELUX CHEMICAL INDUSTRIES
DHLORAMINE KOHS PHARMACEUTICALS
FENAMINE FLOW PHARMACEUTICALS (PVT) LTD.
FENRAM ALBRO PHARMA
HARITON HEALERS LABORATORIES
HISTAGIC LISKO PAKISTAN (PVT) LTD
HISTAMOL EPLA LABORATORIES (PVT) LTD.
HISTOM KARACHI CHEMICAL INDUSTRIES
PHEMIN MARVI LABORATORIES
PHENERMIN SEMOS PHARMACEUTICALS (PVT) LTD.
PHENIR VALOR PHARMACEUTICALS
PIRITON GLAXOSMITHKLINE
REPHENIRAMINE SYNTEX PHARMACEUTICALS
RESMIN RASCO PHARMA
STAITON STANDARD DRUG CO.

Chlorpheniramine (Maleate) [Tabs 10 mg]

CHLORPHENIRAMINE MALEATE SHIFA LABORATORIES.(PVT) LTD.